Replimune Group, Inc.
REPL · NASDAQ
6/30/2025 | 3/31/2025 | 12/31/2024 | 9/30/2024 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 2.35 | -0.12 | -0.24 | 0.32 |
| FCF Yield | -9.38% | -6.98% | -5.19% | -4.73% |
| EV / EBITDA | -9.89 | -10.43 | -14.49 | -16.28 |
| Quality | ||||
| ROIC | -21.74% | -16.07% | -11.90% | -12.75% |
| Gross Margin | 0.00% | 50.00% | 0.00% | 0.00% |
| Cash Conversion Ratio | 0.98 | 0.89 | 0.72 | 0.76 |
| Growth | ||||
| Revenue 3-Year CAGR | -100.00% | -100.00% | -100.00% | -100.00% |
| Free Cash Flow Growth | -45.37% | -4.48% | -28.95% | 19.89% |
| Safety | ||||
| Net Debt / EBITDA | 0.25 | 0.49 | 1.52 | 0.74 |
| Interest Coverage | -45.30 | -39.96 | -33.38 | -29.92 |
| Efficiency | ||||
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Conversion Cycle | -836.92 | -1,296.26 | -646.92 | -841.00 |